First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose

Lin Q, Teer Ba, Jin‐Yuan Ho, Dandan Chen, Ye Cheng, Leiming Wang, Geng Xu, Lixin Xu, Yiqiang Zhou, Yukui Wei, Jianqiang Li, Feng LingFrontiers in Oncology 2021 · DOI

TL;DR

This paper reports on the first-in-human trial of EphA2-redirected CAR T-cells for recurrent glioblastoma, a notoriously difficult-to-treat brain cancer. While the treatment showed preliminary tolerability and transient efficacy in three patients, further studies with adjusted dosing and infusion strategies are needed to improve outcomes.

What Problem Does This Paper Address?

Glioblastoma (GBM) is the most aggressive form of primary brain cancer, with a grim prognosis even with current treatments like surgery, radiation, and chemotherapy. Recurrent GBM is particularly challenging, with limited standard treatment options and a median survival of only about three months. Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of blood cancers, and researchers are exploring its potential for solid tumors, including GBM. EphA2, a protein overexpressed on GBM cells but not significantly in healthy brain tissue, has emerged as a promising target for CAR T-cell therapy. This study addresses the critical need for novel treatments for recurrent GBM by investigating the safety and preliminary efficacy of EphA2-redirected CAR T-cells in a first-in-human clinical trial.

Methods

The study employed a single-arm, dose-escalation, first-in-human pilot trial. Three patients with recurrent, EphA2-positive glioblastoma were enrolled and received a single intravenous infusion of EphA2-redirected CAR T-cells at a starting dose of 1x10^6 cells/kg. Prior to infusion, patients underwent a lymphodepletion regimen consisting of fludarabine and cyclophosphamide.

Key methods for evaluation included:

  • Immunohistochemistry (IHC): To confirm EphA2 expression in tumor samples before enrollment.
  • Flow Cytometry (FCM) and Quantitative Polymerase Chain Reaction (qPCR): To detect and quantify the expansion of CAR T-cells in peripheral blood (PB) and cerebrospinal fluid (CSF).
  • Cytokine Measurement: To monitor levels of inflammatory cytokines (e.g., IL-6, IFN-γ, TNF-alpha) in the plasma.
  • Thoracic X-ray: To assess for pulmonary edema, a potential side effect.
  • Magnetic Resonance Imaging (MRI): To evaluate tumor response using iRANO criteria.
  • National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE): For grading toxicities.
  • ASTCT Consensus: For evaluating cytokine release syndrome (CRS).

Datasets

Not discussed in the paper. The study involved three human patients.

Key Insights and Ideas

  • Intravenous CAR T-cell delivery for GBM is feasible: This study demonstrates that EphA2-redirected CAR T-cells can be safely administered intravenously to patients with recurrent glioblastoma, bypassing the need for invasive intracranial delivery.
  • "On-target, off-tumor" effect is a potential concern: The observed pulmonary edema in two patients, coupled with EphA2 expression in lung tissues, suggests a possible "on-target, off-tumor" effect, where CAR T-cells attack healthy EphA2-expressing lung cells. This highlights the importance of careful target selection and monitoring for such effects.
  • CAR T-cell expansion in CSF indicates blood-brain barrier penetration: The detection of CAR T-cells in the cerebrospinal fluid of one patient suggests that these cells can cross the blood-brain barrier and potentially reach the tumor microenvironment, which is crucial for efficacy in brain cancers.
  • Lymphodepletion may enhance CAR T-cell proliferation: The study notes that the lymphodepletion regimen used might contribute to the observed CAR T-cell expansion, a finding supported by previous research.
  • Transit response is possible, but sustained efficacy is a challenge: While one patient showed a temporary tumor diminishment, the overall response was limited, suggesting that a single dose at this starting level may not be sufficient for long-term control.

Key Results

  • Safety and Tolerability: The treatment was generally tolerable at the starting dose of 1x10^6 cells/kg. Two out of three patients experienced Grade 2 cytokine release syndrome (CRS) accompanied by pulmonary edema, which resolved with dexamethasone treatment. No other organ toxicities, including neurotoxicity, were observed.
  • CAR T-cell Persistence: CAR T-cells showed transient expansion in peripheral blood and persisted for more than four weeks in all three patients. Expansion was also observed in the CSF of one patient. qPCR was found to be more sensitive than FCM for detecting CAR T-cell expansion.
  • Clinical Efficacy:
    • One patient achieved stable disease (SD) at 4 weeks.
  • Two patients experienced progressive disease (PD).
  • Overall survival ranged from 86 to 181 days.
  • One patient experienced a transient diminishment of their tumor.

Limitations and Future Work

  • Small Sample Size: The study involved only three patients, making it difficult to draw definitive conclusions about safety and efficacy.
  • Starting Dose: The reported results are from the initial, starting dose, which may not be optimal for achieving significant clinical benefit.
  • Transit Efficacy: The observed clinical efficacy was transient, suggesting that further optimization is needed.

The authors emphasize the need for future studies with:

  • Adjusted Dosing: Exploring higher or escalated doses of EphA2-redirected CAR T-cells.
  • Modified Infusion Frequency: Investigating the impact of multiple infusions.
  • Further Investigation of "On-target, Off-tumor" Effects: Developing strategies to mitigate potential toxicity to healthy EphA2-expressing tissues.
  • Understanding Immune Response: Further research into the mechanisms of CAR T-cell expansion and persistence in the context of glioblastoma.

Summary updated

Abstract

NCT03423992.
BibTeX
@inproceedings{q2021first,
  author = {Lin Q and Teer Ba and Jin‐Yuan Ho and Dandan Chen and Ye Cheng and Leiming Wang and Geng Xu and Lixin Xu and Yiqiang Zhou and Yukui Wei and Jianqiang Li and Feng Ling},
  title = {{First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.694941},
}
Figure